{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:19:10Z","timestamp":1707524350669},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,16]]},"DOI":"10.7759\/cureus.16431","type":"journal-article","created":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T01:18:32Z","timestamp":1626484712000},"source":"Crossref","is-referenced-by-count":0,"title":["Severe Epistaxis Secondary to Dabrafenib and Trametinib Toxicity in Non-small Cell Lung Carcinoma With Small Bowel Metastasis"],"prefix":"10.7759","author":[{"given":"Keerthi","family":"Gullapalli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama","family":"Mosalem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merryl T","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Watat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borys","family":"Hrinczenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2018.05.06","article-title":"The epidemiology of lung cancer","volume":"7","author":"de Groot PM","year":"2018","unstructured":"de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018, 7:220-33. 10.21037\/tlcr.2018.05.06","journal-title":"Transl Lung Cancer Res"},{"key":"ref2","unstructured":"What Is Lung Cancer?. (2019). Accessed. February 24, 2021: https:\/\/www.cancer.org\/cancer\/lung-cancer\/about\/what-is.html."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2014-0128-RA","article-title":"Biomarkers in lung adenocarcinoma: a decade of progress","volume":"139","author":"Sholl LM","year":"2015","unstructured":"Sholl LM. Biomarkers in lung adenocarcinoma: a decade of progress. Arch Pathol Lab Med. 2015, 139:469-80. 10.5858\/arpa.2014-0128-RA","journal-title":"Arch Pathol Lab Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0642","article-title":"FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations","volume":"23","author":"Odogwu L","year":"2018","unstructured":"Odogwu L, Mathieu L, Blumenthal G, et al.. FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations. Oncologist. 2018, 23:740-5. 10.1634\/theoncologist.2017-0642","journal-title":"Oncologist"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0458","article-title":"Targeting BRAF-mutant non-small cell lung cancer: from molecular profiling to rationally designed therapy","volume":"22","author":"Baik CS","year":"2017","unstructured":"Baik CS, Myall NJ, Wakelee HA. Targeting BRAF-mutant non-small cell lung cancer: from molecular profiling to rationally designed therapy. Oncologist. 2017, 22:786-96. 10.1634\/theoncologist.2016-0458","journal-title":"Oncologist"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.9638","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations","volume":"29","author":"Marchetti A","year":"2011","unstructured":"Marchetti A, Felicioni L, Malatesta S, et al.. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011, 29:3574-9. 10.1200\/JCO.2011.35.9638","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1610456113","article-title":"Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer","volume":"113","author":"Okimoto RA","year":"2016","unstructured":"Okimoto RA, Lin L, Olivas V, et al.. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Proc Natl Acad Sci U S A. 2016, 113:13456-61. 10.1073\/pnas.1610456113","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.11.006","article-title":"Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations","volume":"91","author":"Tissot C","year":"2016","unstructured":"Tissot C, Couraud S, Tanguy R, Bringuier PP, Girard N, Souquet PJ. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations. Lung Cancer. 2016, 91:23-8. 10.1016\/j.lungcan.2015.11.006","journal-title":"Lung Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.10.22","article-title":"Targeting BRAF mutations in non-small cell lung cancer","volume":"8","author":"O'Leary CG","year":"2019","unstructured":"O'Leary CG, Andelkovic V, Ladwa R, et al.. Targeting BRAF mutations in non-small cell lung cancer. Transl Lung Cancer Res. 2019, 8:1119-24. 10.21037\/tlcr.2019.10.22","journal-title":"Transl Lung Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard D","year":"2017","unstructured":"Planchard D, Smit EF, Groen HM, et al.. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017, 18:1307-1316. 10.1016\/S1470-2045(17)30679-4","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24078","article-title":"Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy in metastatic melanoma","volume":"112","author":"Flaherty DC","year":"2015","unstructured":"Flaherty DC, Hoffner BW, Lau BJ, Hamid O, Faries MB. Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy in metastatic melanoma. J Surg Oncol. 2015, 112:844-5. 10.1002\/jso.24078","journal-title":"J Surg Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.890875","article-title":"A case of intracranial hemorrhage caused by combined dabrafenib and trametinib therapy for metastatic melanoma","volume":"15","author":"Lee le M","year":"2014","unstructured":"Lee le M, Feun L, Tan Y. A case of intracranial hemorrhage caused by combined dabrafenib and trametinib therapy for metastatic melanoma. Am J Case Rep. 2014, 15:441-3. 10.12659\/AJCR.890875","journal-title":"Am J Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/s0049-3848(01)00271-7","article-title":"Incorporation of MAP kinases into the platelet cytoskeleton","volume":"103","author":"McNicol A","year":"2001","unstructured":"McNicol A, Shibou TS, Pampolina C, Israels SJ. Incorporation of MAP kinases into the platelet cytoskeleton. Thromb Res. 2001, 103:25-34. 10.1016\/s0049-3848(01)00271-7","journal-title":"Thromb Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2018.1514107","article-title":"Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction","volume":"30","author":"Unsworth AJ","year":"2019","unstructured":"Unsworth AJ, Bye AP, Kriek N, Sage T, Osborne AA, Donaghy D, Gibbins JM. Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction. Platelets. 2019, 30:762-72. 10.1080\/09537104.2018.1514107","journal-title":"Platelets"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1933","article-title":"Src family kinase-mediated and Erk-mediated thromboxane A2 generation are essential for VWF\/GPIb-induced fibrinogen receptor activation in human platelets","volume":"106","author":"Garcia A","year":"2005","unstructured":"Garcia A, Quinton TM, Dorsam RT, Kunapuli SP. Src family kinase-mediated and Erk-mediated thromboxane A2 generation are essential for VWF\/GPIb-induced fibrinogen receptor activation in human platelets. Blood. 2005, 106:3410-4. 10.1182\/blood-2005-05-1933","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13723","article-title":"Live imaging of extracellular signal-regulated kinase and protein kinase A activities during thrombus formation in mice expressing biosensors based on F\u00f6rster resonance energy transfer","volume":"15","author":"Hiratsuka T","year":"2017","unstructured":"Hiratsuka T, Sano T, Kato H, et al.. Live imaging of extracellular signal-regulated kinase and protein kinase A activities during thrombus formation in mice expressing biosensors based on F\u00f6rster resonance energy transfer. J Thromb Haemost. 2017, 15:1487-99. 10.1111\/jth.13723","journal-title":"J Thromb Haemost"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v8.i4.360","article-title":"BRAF V600Q-mutated lung adenocarcinoma with duodenal metastasis and extreme leukocytosis","volume":"8","author":"Qasrawi A","year":"2017","unstructured":"Qasrawi A, Tolentino A, Abu Ghanimeh M, Abughanimeh O, Albadarin S. BRAF V600Q-mutated lung adenocarcinoma with duodenal metastasis and extreme leukocytosis. World J Clin Oncol. 2017, 8:360-5. 10.5306\/wjco.v8.i4.360","journal-title":"World J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/63026-severe-epistaxis-secondary-to-dabrafenib-and-trametinib-toxicity-in-non-small-cell-lung-carcinoma-with-small-bowel-metastasis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:32:23Z","timestamp":1707507143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/63026-severe-epistaxis-secondary-to-dabrafenib-and-trametinib-toxicity-in-non-small-cell-lung-carcinoma-with-small-bowel-metastasis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.16431","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,16]]}}}